Ibuprofen Versus Placebo For Muscle Soreness

Jean Brown Research

Status and phase: Completed; Phase 4

Conditions: Muscle Soreness

Treatments: Drug: Ibuprofen 400 mg; Other: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT03228992

JBR-002

Details and patient eligibility

About

The study will assess the sensitivity of the Delayed Onset Muscle Soreness Model by comparing the safety and efficacy of oral ibuprofen to placebo over 24 hours.

Full description

This is a double-blind, randomized, placebo controlled, parallel group, pilot safety and efficacy study. Healthy male or female subjects who have a history of occasional muscle soreness and are not currently exercising will be asked to volunteer for the study. All subjects will complete an informed consent process prior to study procedures.

The study duration is anticipated to be approximately 4 months. Each subject may be in the study for up to 45 days including screening, run-in, inpatient and outpatient dosing and assessments, follow-up visit and follow-up telephone contact.

Enrollment: 31 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Subjects must meet the following criteria to be included in the study:

1. Male or female subjects aged 18-55 years;

2. In good general health;

3. Non-pregnant, non-lactating female subjects must be:

   1. physically incapable of childbearing potential (postmenopausal for more than 1 year or surgically sterile) or
   2. practicing an acceptable method of contraception (hormonal, barrier with spermicide, intrauterine device, vasectomized or same sex partner, or abstinence). Subjects using hormonal birth control must have been on a stable dose of treatment for at least 30 days and received at least 1 cycle of treatment prior to randomization.

4. History of experiencing muscle pain/soreness after moderately strenuous exercise;

Subjects are excluded from the study if any of the following criteria apply:

1. Currently participating in an exercise regimen.
2. Have an allergy or intolerance to any NSAID, aspirin, acetaminophen or lactose;
3. History of rhabdomyolysis;
4. Have participated in an investigational study within the past 30 days of screening;
5. Are an employee or relative of an employee of the study site (directly involved with the study).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

31 participants in 2 patient groups, including a placebo group

Ibuprofen

Active Comparator group

Description:

Subjects will receive a total of 4 doses of oral ibuprofen 400 mg over a 24 hour period.

Treatment:

Drug: Ibuprofen 400 mg

Placebo

Placebo Comparator group

Description:

Subjects will receive a total of 4 doses of oral placebo over a 24 hour period.

Treatment:

Other: Placebo